Severity of ulcerative colitis is associated with a polymorphism at diamine oxidase gene but not at histamine N-methyltransferase gene

Table 3 Phenotypic characteristics among UC patients classified as carriers or non-carriers of mutations at the ABP1 gene

Phenotypic characteristics	Carriersn = 128	Non-carriersn = 101	OR (95%CI)p value
Male:Female	76:52	62:39	0.79 (0.52-1.62) 0.86
Mean age at diagnosis, yr (range)	37.9 (6-83)	37.1 (17-81)	P = 0.64
Mean duration of disease, yr (range)	11.5 (2-39)	11.0 (2-41)	P = 0.58
Family history of IBD, n (%)	31 (24.2)	21 (20.8)	1.22 (0.62-2.39) 0.54
Smokers at diagnosis, n (%)	28 (21.9)	22 (21.8)	1.01 (0.51-1.98) 0.99
Previous appendectomy, n (%)	5 (3.9)	6 (6.9)	0.64 (0.16-2.47) 0.54
Previous tonsillectomy, n (%)	11 (8.6)	14 (13.9)	0.58 (0.23-1.55) 0.29
Extent of UC
Extensive, n (%)	53 (41.4)	42 (41.6)	1.33 (0.77-2.30) 1
Non-extensive, n (%)	75 (58.6)	59 (58.4)
Extraintestinal clinical manifestations
Cutaneous, n (%)	23 (17.9)	10 (9.9)	1.99 (0.85-4.76) 0.09
Articular, n (%)	49 (38.3)	28 (27.7)	1.64 (0.90-2.99) 0.09
Ocular, n (%)	3 (2.3)	4 (3.9)	0.58 (0.10-3.17) 0.7
Hepatic, n (%)	31 (24.2)	14 (13.9)	1.99 (0.94-4.22) 0.07
Therapy categories
Immunosuppressants, n (%)	41 (70)	17 (30)	2.41 (1.21-4.83) 0.006
Surgery, n (%)1	19 (83)	4 (17)	2.50 (1.28-4.91) 0.003

¹Eighteen of these patients are also included in the subgroup of patients receiving immunosuppressive therapy. Four of the remaining 5 patients in the surgery group were carriers of the variant ABP1 allele.